In recent trading session, Cardiff Oncology Inc (NASDAQ:CRDF) saw 1.18 million shares changing hands at last check today with its beta currently measuring 1.90. Company’s recent per share price level of $6.00 trading at $0.86 or 16.75% at last check today assigns it a market valuation of $268.11M. That most recent trading price of CRDF’s stock is at a discount of -1.0% from its 52-week high price of $6.06 and is indicating a premium of 84.33% from its 52-week low price of $0.94. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.87 million shares which gives us an average trading volume of 1.54 million if we extend that period to 3-months.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Upright in the green today for gaining 16.75%, in the last five days CRDF remained trading in the green while hitting it’s week-highest on Friday, 03/22/24 when the stock touched $6.00 price level, subtracting -4.71% to its value on the day. Cardiff Oncology Inc’s shares saw a change of 305.45% in year-to-date performance and have moved 19.30% in past 5-day. Cardiff Oncology Inc (NASDAQ:CRDF) showed a performance of 255.07% in past 30-days. Number of shares sold short was 1.15 million shares which calculate 4.23 days to cover the short interests.
Cardiff Oncology Inc (CRDF) estimates and forecasts
Statistics highlight that Cardiff Oncology Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 265.90% of value to its shares in past 6 months, showing an annual growth rate of -5.38% while that of industry is 12.00. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -50.80% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $50k for the same. And 4 analysts are in estimates of company making revenue of $60k in the next quarter that will end on Jun 2024. Company posted $83k and $108k of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -39.80% while estimating it to be -44.40% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 35.42% during past 5 years.
CRDF Dividends
Cardiff Oncology Inc is more likely to be releasing its next quarterly report between May 02 and May 06 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
Insiders are in possession of 7.56% of company’s total shares while institution are holding 15.17 percent of that, with stock having share float percentage of 16.41%. Investors also watch the number of corporate investors in a company very closely, which is 15.17% institutions for Cardiff Oncology Inc that are currently holding shares of the company. Vanguard Group Inc is the top institutional holder at CRDF for having 1.91 million shares of worth $10.82 million. And as of Dec 30, 2023, it was holding 4.28% of the company’s outstanding shares.
The second largest institutional holder is Laurion Capital Management, LP, which was holding about 0.72 million shares on Dec 30, 2023. The number of shares represents firm’s hold over 1.62% of outstanding shares, having a total worth of $4.09 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 30, 2023, the former fund manager was holding 1.25 million shares of worth $7.1 million or 2.81% of the total outstanding shares. The later fund manager was in possession of 0.59 million shares on Dec 30, 2023, making its stake of worth around $3.34 million in the company or a holder of 1.32% of company’s stock.
